| 1. |
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1): 11-30.
|
| 2. |
Advani P, Moreno-Aspitia A. Current strategies for the prevention of breast cancer. Breast Cancer (Dove Med Press), 2014, 6: 59-71.
|
| 3. |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108.
|
| 4. |
Breakthrough of the year 2013. Notable developments. Science, 2013, 342(6165): 1435-1441.
|
| 5. |
薛聰, 彭柔君, 安欣, 等. CD8+ 淋巴細胞浸潤對可手術乳腺癌預后的影響. 臨床腫瘤學雜志, 2014, 19(10): 896-900.
|
| 6. |
何建明, 黃湛, 吳家豪, 等. CD8+ 腫瘤浸潤淋巴細胞與乳腺癌預后的關系. 中國普通外科雜志, 2013, 22(11): 1475-1478.
|
| 7. |
爭鳴, 張欣, 郭慧芳, 等. CD147 介導 CD4+ 腫瘤浸潤淋巴細胞促進乳腺癌進展. 細胞與分子免疫學雜志, 2015, 31(7): 961-964.
|
| 8. |
李文華, 張瑩. 乳腺癌復發轉移灶與原發灶中 ER、PR、HER-2、p53、Ki-67 的表達差異. 臨床與實驗病理學雜志, 2016, 32(7): 727-730.
|
| 9. |
Smith HA, Kang Y. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl), 2013, 91(4): 411-429.
|
| 10. |
Starska K, G?owacka E, Kulig A, et al. Prognostic value of the immunological phenomena and relationship with clinicopathological characteristics of the tumor–the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ lymphocytes in squamous cell laryngeal carcinoma. Part Ⅱ. Folia Histochem Cytobiol, 2011, 49(4): 593-603.
|
| 11. |
孫宇, 鄒燕鵬, 鄧素華, 等. 不同分子分型乳腺癌原發灶內 CD4+、CD8+T 淋巴細胞的表達差異研究. 中國臨床研究, 2016, 29(2): 153-156, 161.
|
| 12. |
唐聃, 楊偉明, 姚新生, 等. 乳腺癌患者外周血 CD4+ CD25+ Foxp3+ 調節性 T 細胞水平的檢測及意義. 中國普通外科雜志, 2014, 23(5): 612-617.
|
| 13. |
曾繁余, 彭德珍, 張珊, 等. 乳腺癌患者外周血中 T 細胞亞群與淋巴結轉移和組織學分級的關系. 中國普通外科雜志, 2015, 24(11): 1559-1564.
|
| 14. |
Jia Y, Xu L, Lin Q, et al. Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes. Med Oncol, 2014, 31(6): 981.
|
| 15. |
Riazi Rad F, Ajdary S, Omranipour R, et al. Comparative analysis of CD4+ and CD8+ T cells in tumor tissues, lymph nodes and the peripheral blood from patients with breast cancer. Iran Biomed J, 2015, 19(1): 35-44.
|
| 16. |
拉宗, 王建霞, 邢樹剛, 等. 乳腺浸潤性導管癌微環境中 CD4 和 CD8 陽性 T 細胞表達與血管新生的關聯性分析. 吉林大學學報 (醫學版), 2014, 40(5): 1069-1073.
|
| 17. |
Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol, 2011, 29(15): 1949-1955.
|
| 18. |
于海明, 焦順昌, 楊俊蘭, 等. 乳腺癌原發灶 T 淋巴細胞浸潤與預后的關系. 中國醫學科學院學報, 2013, 35(2): 199-206.
|
| 19. |
Perret R, Sierro SR, Botelho NK, et al. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res, 2013, 73(22): 6597-6608.
|
| 20. |
Gu-Trantien C, Loi S, Garaud S, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest, 2013, 123(7): 2873-2892.
|
| 21. |
Macchetti AH, Marana HR, Silva JS, et al. Tumor-infiltrating CD4+ T lymphocytes in early breast cancer reflect lymph node involvement. Clinics (Sao Paulo), 2006, 61(3): 203-208.
|
| 22. |
Hong CC, Yao S, McCann SE, et al. Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res Treat, 2013, 139(2): 477-488.
|
| 23. |
吳朔, 姜翠, 徐君南, 等. CD4+/CD8+ 比值在乳腺癌患者臨床病理分析及預后評估中的意義. 現代腫瘤醫學, 2016, 24(18): 2885-2888.
|
| 24. |
何偉華, 王長松, 贠田, 等. 乳腺癌患者腋窩淋巴結 T 細胞亞群檢測及其臨床意義. 免疫學雜志, 2013, 29(8): 672-676.
|
| 25. |
俞新爽, 韓俊慶, 王興文, 等. 乳腺癌患者細胞免疫水平與預后危險因素的關系及臨床意義. 山東大學學報 (醫學版), 2007, 45(9): 934-937.
|
| 26. |
Hald SM, Bremnes RM, Al-Shibli K, et al. CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy. Lung Cancer, 2013, 80(2): 209-215.
|
| 27. |
周瑋, 魏海云, 牛佳木. COX-2、CD4 及 CD8 在胃癌組織中的表達及其意義. 實用癌癥雜志, 2012, 27(3): 250-252.
|
| 28. |
孫立平, 劉軍, 金昊, 等. CD4+ CD25+ 調節性 T 細胞對乳腺癌細胞上皮間質轉化和 ALDH1+ 干樣細胞的影響. 中國腫瘤臨床, 2016, 43(5): 177-182.
|
| 29. |
江飛云, 吳名彩, 倪觀太. 乳腺癌患者 BRCA 基因突變檢測及 P53 蛋白表達分析. 中國病原生物學雜志, 2017, 12(1): 79-82.
|